Benjamin Al,Nicholas Holzscheck,Stephan Traidl,Sina Freimooser,Lennart M Roesner,Hendrik Mießner,Oliver Dittrich-Breiholz,Hendrik Reuter,Thomas Werfel,Judith A Seidel
{"title":"Subclinical inflammation precedes atopic dermatitis relapses.","authors":"Benjamin Al,Nicholas Holzscheck,Stephan Traidl,Sina Freimooser,Lennart M Roesner,Hendrik Mießner,Oliver Dittrich-Breiholz,Hendrik Reuter,Thomas Werfel,Judith A Seidel","doi":"10.1016/j.jaci.2025.03.033","DOIUrl":null,"url":null,"abstract":"BACKGROUND\r\nAtopic dermatitis (AD), a widespread inflammatory skin disease, is characterized by disease recurrence, even after successful treatment. Past clinical research has mainly focused on understanding the active disease state as opposed to what drives and triggers AD relapses in the first place.\r\n\r\nOBJECTIVE\r\nTo elucidate the unknown molecular mechanisms behind AD relapses.\r\n\r\nMETHODS\r\nAn observational clinical study with patients in remission was conducted, comparing biopsies from skin that would relapse within the next weeks with skin that stayed in remission using single-cell-RNA sequencing and immunohistochemistry analyses.\r\n\r\nRESULTS\r\nSigns of subclinical inflammation were present in the clinically healthy appearing pre-relapse state. On the one hand, we detected molecular signals reminiscent of active AD, such as epidermal barrier dysregulation, chemokine signaling, increased vascular permeability and first signs of T cell activity and infiltration. On the other hand, we also observed signals for processes specific to the pre-relapse state, including epidermal growth factor receptor (EGFR) signaling and macrophage phagocytosis.\r\n\r\nCONCLUSION\r\nTaken together, this work uncovers novel aspects of AD development, and putatively paves the way for new therapeutic approaches that are specifically designed to prevent AD recurrence.","PeriodicalId":14936,"journal":{"name":"Journal of Allergy and Clinical Immunology","volume":"51 1","pages":""},"PeriodicalIF":11.4000,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Allergy and Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jaci.2025.03.033","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
Abstract
BACKGROUND
Atopic dermatitis (AD), a widespread inflammatory skin disease, is characterized by disease recurrence, even after successful treatment. Past clinical research has mainly focused on understanding the active disease state as opposed to what drives and triggers AD relapses in the first place.
OBJECTIVE
To elucidate the unknown molecular mechanisms behind AD relapses.
METHODS
An observational clinical study with patients in remission was conducted, comparing biopsies from skin that would relapse within the next weeks with skin that stayed in remission using single-cell-RNA sequencing and immunohistochemistry analyses.
RESULTS
Signs of subclinical inflammation were present in the clinically healthy appearing pre-relapse state. On the one hand, we detected molecular signals reminiscent of active AD, such as epidermal barrier dysregulation, chemokine signaling, increased vascular permeability and first signs of T cell activity and infiltration. On the other hand, we also observed signals for processes specific to the pre-relapse state, including epidermal growth factor receptor (EGFR) signaling and macrophage phagocytosis.
CONCLUSION
Taken together, this work uncovers novel aspects of AD development, and putatively paves the way for new therapeutic approaches that are specifically designed to prevent AD recurrence.
期刊介绍:
The Journal of Allergy and Clinical Immunology is a prestigious publication that features groundbreaking research in the fields of Allergy, Asthma, and Immunology. This influential journal publishes high-impact research papers that explore various topics, including asthma, food allergy, allergic rhinitis, atopic dermatitis, primary immune deficiencies, occupational and environmental allergy, and other allergic and immunologic diseases. The articles not only report on clinical trials and mechanistic studies but also provide insights into novel therapies, underlying mechanisms, and important discoveries that contribute to our understanding of these diseases. By sharing this valuable information, the journal aims to enhance the diagnosis and management of patients in the future.